EAM
JAZZ icon

Eukles Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Eukles Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-514
Closed -$63.3K – 226
2024
Q4 		$63.3K Sell
514
-39
-7% -$4.6K 0.03% 103
2024
Q3 		$61.6K Sell
553
-64
-10% -$7.01K 0.02% 104
2024
Q2 		$65.9K Sell
617
-79
-11% -$8.69K 0.03% 102
2024
Q1 		$83.8K Sell
696
-1,484
-68% -$182K 0.04% 98
2023
Q4 		$268K Sell
2,180
-144
-6% -$18K 0.13% 96
2023
Q3 		$301K Hold
2,324
– – 0.16% 91
2023
Q2 		$288K Hold
2,324
– – 0.15% 88
2023
Q1 		$340K Buy
2,324
+13
+0.6% +$1.92K 0.18% 85
2022
Q4 		$368K Hold
2,311
– – 0.21% 80
2022
Q3 		$308K Buy
2,311
+148
+7% +$22.5K 0.2% 80
2022
Q2 		$337K Buy
2,163
+1
+0% +$154 0.21% 84
2022
Q1 		$337K Sell
2,162
-82
-4% -$11.9K 0.18% 85
2021
Q4 		$286K Sell
2,244
-223
-9% -$29.3K 0.14% 92
2021
Q3 		$321K Buy
2,467
+427
+21% +$64.5K 0.18% 87
2021
Q2 		$362K Buy
2,040
+244
+14% +$42.3K 0.2% 79
2021
Q1 		$295K Buy
1,796
+197
+12% +$32.4K 0.19% 81
2020
Q4 		$264K Sell
1,599
-148
-8% -$22K 0.18% 79
2020
Q3 		$249K Buy
1,747
+31
+2% +$3.84K 0.19% 80
2020
Q2 		$189K Hold
1,716
– – 0.16% 85
2020
Q1 		$171K Buy
1,716
+872
+103% +$113K 0.18% 83
2019
Q4 		$126K Hold
844
– – 0.1% 97
2019
Q3 		$108K Hold
844
– – 0.09% 98
2019
Q2 		$120K Buy
844
+19
+2% +$2.55K 0.1% 97
2019
Q1 		$118K Hold
825
– – 0.11% 94
2018
Q4 		$102K Buy
+825
New +$122K 0.11% 89

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Eukles Asset Management's JAZZ Position: Q1 2025 in Review

Eukles Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2025, closing a stake of 514 shares — an estimated $63.3K sold.

Eukles Asset Management first reported a position in JAZZ in Q4 2018 and held it in 25 quarters. The position peaked at $368K in Q4 2022. 551 funds tracked by Wall St. Rank hold JAZZ as of Q1 2025.

  • Eukles Asset Management reported no remaining Jazz Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Eukles Asset Management sold 514 Jazz Pharmaceuticals shares in Q1 2025, an estimated $63.3K.
  • Eukles Asset Management first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 25 quarters.
  • Eukles Asset Management's Jazz Pharmaceuticals position peaked at $368K in Q4 2022.
  • 551 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2025.

Based on Eukles Asset Management's 13F filing for Q1 2025, filed 29 Apr 2025.